Schiff Nutrition International Names Shane Durkee Senior Vice President, Research and Development
05 Outubro 2011 - 9:00AM
Business Wire
Schiff Nutrition International, Inc., (NYSE:WNI), appointed
Shane Durkee Senior Vice President, Research and Development,
effective October 3, 2011.
Tarang Amin, president and chief executive officer, stated: “We
welcome Shane and believe his proven track record in driving
nutritional supplements innovation will contribute significantly to
accelerating our new product program and organic growth.
Furthermore, his energy, enthusiasm and passion will complement our
senior leadership team.”
“I am excited to join Schiff Nutrition and help the company
build its strong portfolio of brands,” stated Durkee. “I look
forward to working with the management team to help advance the
growth strategy of building premium brands, leading innovation,
expanding the channel and geographic footprint of the company,
pursuing acquisitions, and driving world-class operations.”
Durkee, 39, has over 16 years of consumer products research and
development experience in leading teams in innovation, product
development and medical science. Most recently, he was the
Director, Global Innovation and New Technology at Bayer Consumer
Care AG in Basel, Switzerland. In this position, he led product
innovation and development within the Nutritional, Dermatologic and
Gastrointestinal business units, which had over €2 billion in
annual sales. He also served in R&D leadership roles working on
Bayer’s U.S. branded nutritional business, including One-A-Day®,
Flintstones™ and CitraCal®. Prior to joining Bayer, Durkee held
R&D leadership roles with TwinLab and Nutraceutical
Corporation. Durkee holds a B.S. in Microbiology and an M.B.A. He
has served as a member of the Senior Scientific Advisory Council
for the Council for Responsible Nutrition and as a science advisory
board member at Virgo Publishing.
About Schiff Nutrition
Schiff Nutrition International, Inc. develops, manufactures,
markets and distributes branded and private label vitamins,
nutritional supplements and nutrition bars in the United States and
throughout the world. Schiff’s portfolio of well-known brands
includes Schiff Move Free®, Schiff® Vitamins, Schiff MegaRed®,
Schiff Mega-D3®, Tiger's Milk®, Schiff Sustenex®, and Schiff
Digestive Advantage®. To learn more about Schiff, please visit the
web site www.schiffnutrition.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that are based
on management’s beliefs and assumptions, current expectations,
estimates, and projections. These statements are subject to known
and unknown risks and uncertainties, certain of which are beyond
the company’s ability to control or predict, and therefore, actual
results may differ materially. For example, statements concerning
Schiff Nutrition’s financial condition, possible or expected
results of operations, commercialization of new products, growth
opportunities and plans of management are all forward-looking
statements. Any forward-looking statements are made pursuant to the
Private Securities Litigation Reform Act of 1995 and, as such,
speak only as of the date hereof. Schiff Nutrition disclaims any
obligation to update any forward-looking statements whether as a
result of new information, future events or otherwise. You are
cautioned not to place undue reliance on these forward-looking
statements.
Important factors that may cause actual results of Schiff
Nutrition to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited
to: dependence on sales of Schiff Move Free product and the
joint care category, dependence on sales of Schiff MegaRed product,
dependence on individual customers, adverse publicity or consumer
perception regarding our nutritional supplements and/or their
ingredients, similar products distributed by other companies or the
nutritional supplement industry generally, the impact of
competitive products and pricing pressure (including expansion of
private label products), the inability to successfully bid on new
and existing private label business, the impact of raw material
pricing, availability and quality (particularly relating to joint
care products and ingredients from third-party suppliers outside
the United States, including China), claims that our products
infringe the intellectual property rights of others, the inability
to enforce or protect our intellectual property rights and
proprietary techniques against infringement, the inability to
successfully launch and maintain sales (especially in the joint
care and omega-3 categories) outside of the United States while
maintaining the integrity of the products sold and complying with
local regulations, the inability to appropriately respond to
changing consumer preferences and demand for new products, the
inability to gain or maintain market distribution for new products
or product enhancements, including products in the probiotic space,
litigation and government or administrative regulatory action in
the United States and internationally, including FDA enforcement
and product liability claims, the inability or increased cost to
obtain sufficient levels of product liability and general
insurance, the inability to comply with existing or new
regulations, both in the United States and abroad, and adverse
actions regarding product formulation, claims or advertising,
product recalls or a significant amount of product returns,
dependence on a single manufacturing facility and potential
disruptions of our manufacturing operations, the inability to find
strategic transaction opportunities or the inability to
successfully consummate or integrate a strategic transaction
(including the inability to successfully integrate the assets
recently acquired from Ganeden), the inability to maintain or
attract key personnel, interruptions to our information technology
systems, control by our principal stockholders, and other factors
indicated from time to time in the company’s SEC reports, copies of
which are available upon request from the company’s investor
relations department or may be obtained at the SEC's web site
(www.sec.gov). These risks and
uncertainties should be carefully considered before making an
investment decision with respect to shares of our common stock.
Schiff Nutrit (NYSE:WNI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Schiff Nutrit (NYSE:WNI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024